Trial 0C-19-4

Phase 1 Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Lorlatinib in Advanced Cancer Patients

Type: Treatment
Phase: Phase I
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Immunotherapy
Randomized: No
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Anthony El-Khoueiry, M.D.
Other Trial Staff: Yan Ning, D.M., Cristina De Leon, Coordinator, Chi Nguyen, Coordinator, Maria Sharma, Coordinator, Leila Andres, Coordinator, Nicole Jensen, Coordinator, Edwin Smura, Coordinator, Rishi Bhavsar, Coordinator, Mary Ordaz, D.M., Anayansi Miloud, D.M., Xiomara Menendez, Coordinator, Jessica Levano, Coordinator, Taison Tran, Coordinator, Khatchik Karakozian, D.M., Niranjan Bhatt, D.M., Atessa Kiani, Coordinator, Alda Inveiss, Coordinator, Lauren Wagner, Coordinator, Negeen Izadian, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.